Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E134.80 EPS (ttm)3.07 Insider Own1.10% Shs Outstand102.62M Perf Week-2.35%
Market Cap42.47B Forward P/E33.84 EPS next Y12.23 Insider Trans-22.68% Shs Float75.65M Perf Month1.43%
Income348.10M PEG7.36 EPS next Q2.70 Inst Own72.80% Short Float6.06% Perf Quarter0.20%
Sales2.82B P/S15.06 EPS this Y-19.40% Inst Trans1.08% Short Ratio5.59 Perf Half Y18.24%
Book/sh25.05 P/B16.52 EPS next Y13.84% ROA9.70% Target Price443.32 Perf Year22.24%
Cash/sh8.78 P/C47.16 EPS next 5Y18.31% ROE14.40% 52W Range269.50 - 437.64 Perf YTD0.88%
Dividend- P/FCF103.53 EPS past 5Y41.20% ROI12.20% 52W High-5.44% Beta0.88
Dividend %- Quick Ratio3.20 Sales past 5Y49.40% Gross Margin92.70% 52W Low53.56% ATR11.42
Employees2925 Current Ratio3.30 Sales Q/Q31.40% Oper. Margin29.70% RSI (14)49.94 Volatility2.47% 2.82%
OptionableYes Debt/Eq0.22 EPS Q/Q-1.00% Profit Margin12.30% Rel Volume0.99 Prev Close419.87
ShortableYes LT Debt/Eq0.18 EarningsFeb 10 BMO Payout0.00% Avg Volume819.78K Price413.84
Recom1.90 SMA200.59% SMA500.74% SMA20014.34% Volume810,149 Change-1.44%
Feb-19-15Downgrade ROTH Capital Buy → Neutral $461
Feb-17-15Reiterated Argus Buy $430 → $450
Feb-11-15Reiterated UBS Neutral $417 → $412
Feb-11-15Reiterated RBC Capital Mkts Outperform $480 → $490
Feb-02-15Reiterated RBC Capital Mkts Outperform $477 → $480
Nov-20-14Reiterated Brean Capital Buy $390 → $450
Nov-19-14Reiterated ROTH Capital Buy $422 → $461
Nov-11-14Reiterated Argus Buy $375 → $430
Nov-05-14Reiterated RBC Capital Mkts Outperform $373 → $410
Oct-24-14Reiterated Canaccord Genuity Buy $350 → $460
Sep-02-14Reiterated Brean Capital Buy $380 → $390
Aug-06-14Reiterated RBC Capital Mkts Outperform $349 → $373
Jul-21-14Initiated Argus Buy $375
Apr-16-14Initiated Canaccord Genuity Buy $350
Feb-13-14Downgrade Oppenheimer Outperform → Perform $310 → $325
Sep-30-13Reiterated Oppenheimer Outperform $300 → $310
Aug-22-13Initiated Oppenheimer Outperform $300
May-17-13Initiated UBS Neutral $290
May-06-13Reiterated RBC Capital Mkts Outperform $270 → $286
May-06-13Reiterated Barclays Overweight $275 → $305
Feb-27-15 11:30AM  Novartis treatment for vision loss meets goals in study Reuters
09:30AM  The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Zacks
09:00AM  Up and Down the Ladder: The Latest Comings & Goings at Alkermes, Charles River Labs and at The Wall Street Journal
07:02AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Feb-26-15 08:40AM  EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion PR Newswire
Feb-25-15 07:29PM  Lightning Round: This group goes higher tomorrow at CNBC
Feb-23-15 07:02PM  Cramer Remix: Where's the Nasdaq bubble? at CNBC
07:00PM  Cramer: Watch out - regulators are gunning for these stoc... CNBC
06:50PM  Lightning Round: Don't listen to this CEO at CNBC
12:01AM  Regeneron Shares Reach Full Valuation at Barrons.com
Feb-20-15 07:42PM  Lightning Round: This stock's got to get game back at CNBC
08:30AM  FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Company Spotlight
Feb-19-15 06:24PM  Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Zacks +5.13%
05:04PM  Update: Regeneron: Too Much Excitement About Eylea News? at Barrons.com
04:49PM  Regeneron Pharms downgraded by ROTH Capital Briefing.com
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
11:55AM  Regeneron Tops Roche in Eye Drug Study That May Boost Sales at Bloomberg
07:38AM  Regeneron: Need fair drug prices CNBC
Feb-18-15 05:00PM  Regeneron drug tops rivals in some vision loss cases at CNBC
05:00PM  Regeneron Beats Genentech In Rare Face Off Over Diabetes-Related Vision Loss at Forbes
05:00PM  NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab PR Newswire
04:07PM  No, The New Cholesterol Drugs From Sanofi And Amgen Aren't Going To Cost $150 Billion A Year at Forbes
12:02PM  Regeneron Beats on Q4 Earnings Driven by Eylea Sales (revised) - Analyst Blog Zacks
08:00AM  New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels PR Newswire
Feb-17-15 07:31PM  Lightning Round: I'm putting my chips on this at CNBC
07:16PM  Cramer Remix: Nasdaq isn't worth worrying about at CNBC
05:55PM  CVS urges cost controls for new cholesterol drugs Reuters
02:39PM  Street Talk: REGN, CLF, MU, BID & PEGI CNBC
Feb-14-15 07:07PM  10-K for Regeneron Pharmaceuticals, Inc. Company Spotlight
Feb-13-15 09:30AM  Regeneron Announces Upcoming 2015 Investor Conference Presentations PR Newswire
07:00AM  Regeneron Pharmaceuticals, Inc. (REGN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-12-15 07:19PM  Lightning Round: It's part of a major revolution at CNBC
04:40PM  REGENERON PHARMACEUTICALS INC Files SEC form 10-K, Annual Report EDGAR Online
09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
Feb-11-15 06:55PM  Lightning Round: Charts are lining up for this group at CNBC
10:26AM  Regeneron's Expanded Pipeline Not A Concern For Morgan Stanley Benzinga
Feb-10-15 07:31PM  Lightning Round: This stock needs to split up at CNBC
07:11PM  Cramer Remix: You need to see this Apple news at CNBC
04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
11:56AM  Regeneron Pharmaceuticals (REGN) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
09:28AM  Regeneron Beats on Q4 Earnings Driven by Eylea Sales - Analyst Blog Zacks
08:30AM  Regeneron Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
08:04AM  Regeneron (REGN) Beats on Q4 Earnings, Provides 2015 View - Tale of the Tape Zacks
07:32AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:11AM  Regeneron revenue beats Street on strong Eylea sales Reuters
07:07AM  Q4 2014 Regeneron Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:54AM  Regeneron misses 4Q profit forecasts AP
06:41AM  Regeneron's profit rises about 14 pct on strong Eylea sales Reuters
06:30AM  Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results PR Newswire
05:57AM  Wall Street watches Coca-Cola, Greece debt woes at CNBC
Feb-09-15 06:04PM  Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog Zacks
03:50PM  2 Hot Medical Stocks Report Earnings On Tuesday at Investor's Business Daily
03:20PM  Will Regeneron (REGN) Beat Q4 Earnings on Eylea Sales? - Analyst Blog Zacks
02:50PM  Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog Zacks
Feb-06-15 07:00PM  Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan at TheStreet
06:09PM  Cramer game plan: Next week's hot stocks to watch at CNBC
06:00PM  Cramer's earnings plan: MAS, CVS & more CNBC
04:04PM  What to Watch in the Week Ahead and on Monday, Feb. 9 Reuters
09:04AM  Sanofi Misses on Q4 Earnings, Maintains Diabetes Guidance - Analyst Blog Zacks
Feb-05-15 01:31PM  Highlights From Viking Globals Investor Letter: Alibaba Group Holding Ltd (BABA), Regeneron Pharmaceuticals Inc (REGN) at Insider Monkey
06:41AM  Up To Speed: Refineries strike continues with no resolution, but a new offer (Video) at American City Business Journals
Feb-04-15 06:13PM  Cramer: How to make money in wild market swings at CNBC
12:13PM  Pricing wars heat up over hepatitis C drugs at CNBC
09:22AM  Cramer's Mad Dash: GILD & CMG CNBC
Feb-03-15 06:22PM  Energy Stocks Lead Mutual Funds' Dive Into Red In Jan. at Investor's Business Daily
04:05PM  Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog Zacks
02:30PM  Will Teva (TEVA) Earnings Surprise on Higher Sales? - Analyst Blog Zacks
Feb-02-15 04:40PM  Will Pacific Biosciences (PACB) Surprise on Earnings in Q4? - Analyst Blog Zacks
02:40PM  Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? - Analyst Blog Zacks
Jan-30-15 12:15PM  Upside play in biotech space CNBC
12:15PM  Obama unveils precision medicine initiative CNBC
07:03AM  White House targets precision medicine CNBC
06:00AM  Obama's $215 Million DNA Sequencing Project Is A Great Idea at Forbes
06:00AM  Obama seeks $215 million for 'precision medicine' at CNBC
Jan-29-15 02:41PM  Vertex head of research, Broad co-founder David Altshuler to meet with Obama Friday at American City Business Journals
Jan-28-15 05:06PM  Drugmakers get mysterious invites to White House at CNBC
04:55PM  Regeneron, Vertex execs heads to White House CNBC
Jan-27-15 06:50PM  Regeneron/Sanofi's PCSK9 Drug Gets FDA Priority Review - Analyst Blog Zacks
04:45PM  Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Zacks
03:20PM  Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Zacks
Jan-26-15 05:22PM  Medivation CEO's Planned Sale Hits $10.8M in Stock at Barrons.com
06:53AM  Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune
02:46AM  Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes
01:00AM  Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race at Bloomberg
01:00AM  Regeneron/Sanofi cholesterol drug gets FDA priority review Reuters
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA PR Newswire
Jan-23-15 07:32AM  EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union PR Newswire
Jan-22-15 03:45PM  Ebola vaccine trials to begin in Liberia at CNBC
04:13AM  US investors double down on biotech bets at Financial Times
Jan-20-15 06:56PM  Lightning Round: I prefer this to Alibaba at CNBC
04:43PM  The 5 Biggest Biotech Stocks Benzinga
10:00AM  Benefits firms shouldn't play drug favorites: CEO at CNBC
09:55AM  Cramer's Stop Trading: Biotech hangover CNBC
07:41AM  Regeneron CEO: Choice, not price best for patients CNBC
Jan-14-15 02:48PM  New York drug developer's big money maker had nearly $1.74B in sales last year at American City Business Journals
Jan-13-15 01:32PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
10:32AM  Veteran Analyst's Top Health-Care Picks for 2015 at Barrons.com
Jan-12-15 01:10AM  Sanofi, Regeneron submit new cholesterol drug to EMA for review Reuters
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA PR Newswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM